Europe is a significant market for drugs from a global perspective. Both cannabis and synthetic narcotics are produced in Europe; the manufacturing of cannabis is primarily for domestic use, and certain synthetic drugs are produced for export to other areas of the world.
Europe is home to around one-third of all psilocybin experimental research. The University of Zurich, University Hospital Basel, and Imperial College London are the three main centers for psychedelic research in Europe, and they are all now engaged in psilocybin clinical or neurobiological studies and devoted to raising awareness, and accessibility to, psychedelic treatments and associated medical care.
The approach adopted by Europe is based on the use of psychedelics in therapy is safe when done so in environments that are regulated and encouraging, according to research. Europe’s psychedelic retreats have proven to be a highly effective means of reducing the mental and emotional strain brought on by upsetting past events.
European countries like the Netherlands believe that in an appropriate environment, working with psychoactive substances with a well-focused goal can lead to healing, self-transformation, expanded awareness, and quick self-development. People from all over the globe come to the Netherlands every year to take part in retreats for spiritual growth and healing. These psychedelic retreats have shown to be a highly effective means of reducing the mental and emotional strain brought on by upsetting previous events. For those interested in using ayahuasca, psilocybin(same psychedelic effects as the mushroom itself) is recommended.
Europe’s idea is based on that the primary advantage of psychedelic innovative treatments results from the fusion of psychedelic medication and therapy. When used in conjunction with qualified therapists, they can provide a therapeutic window of time for individuals to address the underlying reasons for their mental health issues.
Europe’s acceptance to incorporate indigenous practices and reciprocity in mind and with resources to commercialize psychedelics in the market, initiatives to alter public attitudes toward psychedelic-assisted treatments, increasing knowledge of scientific breakthroughs, and, eventually, improve brain health for Europeans have been into a play.
References
European Drug Report 2021,https://www.emcdda.europa.eu/edr2021_en
Belouin, Sean J.; Henningfield, Jack E. (2018). Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology, (), S0028390818300753–.doi:10.1016/j.neuropharm.2018.02.018
Nichols DE. Psychedelics. Pharmacol Rev. 2016 Apr;68(2):264-355. doi:
10.1124/pr.115.011478. Erratum in: Pharmacol Rev. 2016 Apr;68(2):356. PMID: 26841800;
PMCID: PMC4813425.
Importance of Professional Counseling: A friend or family member may listen to you, but they aren’t professionally, technically qualified or experienced to offer you professional advice. If you wish you can contact us at MindTribe to receive help from our team of expert psychologists.
About MindTribe.in.
MindTribe Founder Dr. Prerna Kohli, India’s eminent psychologist, established the company to leverage the strength of the online to make counseling affordable and accessible to everyone. MindTribe provides counseling, workshops, support groups, forums, and eLearning.
About the Author.
Muskan Nayyar is a psychologist at MindTribe.in. You can learn more about her by clicking here
Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the official policy or position of MindTribe.in, the Founders, or management team.
Acknowledgement: All images used are open source and from Unsplash.